secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2025-07-14T23:59:59+00:00
Accession:  0001213900-25-063475
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CERo Therapeutics enters new common stock purchase agreement for up to $17.5M with Keystone Capital
--------------------------------------------------------------------------------

- New Purchase Agreement allows CERo to issue and sell up to $17,490,897 of common stock to Keystone Capital, minus any additional proceeds from prior November deal after June 30, 2025.
- Fixed purchases per notice capped at lower of 10,000 shares or $100,000; VWAP purchases aggregate limit of $10M.
- Beneficial ownership limitation of 4.99% per purchase.
- Registration Rights Agreement filed concurrently for shares issued.
- Replaces prior equity lines from Feb '24 and Nov '24 which had raised ~$7.5M combined.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025063475/0001213900-25-063475-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025063475/ea0248789-8k_cero.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-063475

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer